Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
fighting games
Popular Articles
Revitol Cellulite Cream

Essentialis Meets Primary Endpoint In Phase 2b Trial Of DCCR For Treatment Of Hypertriglyceridemia And Is Granted Extensive Patent Coverage In The US
Essentialis Inc, a clinical stage pharmaceutical company, announced that it met its primary endpoint of statistically significant triglyceride reduction in a 90-patient Phase 2b trial of DCCR in dyslipidemic patients. The study encompassed both patients with very high triglycerides and mixed dyslipidemia and included normal weight, overweight and obese patients presenting with or without hypertension. Don't forget to buy zoloft online no prescription.

QualityMetric Offers Way To Measure The Impact Of Sleep Problems On Individuals And Groups
There are few things as vital to health and well-being as a good night"s sleep. Yet millions of us -- nearly 50 million according to the National Sleep Foundation -- suffer from chronic sleep problems or disorders. Every year, more and more scientific studies are showing correlations between poor or insufficient sleep and disease. Now there is a simple, easy way to quantify and measure sleep problems with patient populations.

generic viagra online


News of the day
Fluidigm Introduces New TOPAZ(R) Protein Crystallization Chip That Provides A "Screen To Beam" Solution
In the rarified world of protein crystal hunters, Fluidigm"s TOPAZ® system is the tool that has helped researchers solve the structures of proteins from the Ebola Virus and Avian Flu Influenza. Now Fluidigm is introducing its new 1.96 Diffraction Capable (DC) integrated fluidic circuit which will allow researchers something they have long sought - direct screen-to-beam capabilities without the need to physically harvest a crystal from the device.
Public Health

Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced Her2-Positive Breast Cancer

Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says: "This study suggests that patients with HER2 positive advanced breast cancer who are no longer responding to Herceptin or chemotherapy may benefit from the combined Herceptin and DM1 treatment. Whilst many patients responded to the treatment in this trial, further larger studies will be needed to assess the full benefits. "There are limited treatments available for those with advanced breast cancer so improving the range of options is always welcome and we look forward to the results of the ongoing trials of this treatment." Breakthrough Breast Cancer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009